Screener
Cogent Biosciences, Inc. COGT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $13,744 | $9,504 |
| Accrued expenses and other current liabilities | 42,854 | 52,902 |
| Operating lease liabilities | 1,383 | 1,547 |
| Total current liabilities | 57,981 | 63,953 |
| Convertible senior notes, net | 223,173 | 222,895 |
| Operating lease liabilities, net of current portion | 14,097 | 14,355 |
| Other liabilities | 62 | 33 |
| Total liabilities | 295,313 | 301,236 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s total current liabilities?
- Cogent Biosciences, Inc. (COGT) reported total current liabilities of $57.98M in Q1 2026.
- How has Cogent Biosciences, Inc.'s total current liabilities changed year-over-year?
- Cogent Biosciences, Inc.'s total current liabilities increased by 17.6% year-over-year, from $49.32M to $57.98M.
- What is the long-term trend for Cogent Biosciences, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s total current liabilities has grown at a 37.3% compound annual growth rate (CAGR), from $13.09M to $63.95M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Cogent Biosciences, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude